Preparing For Commercial Launch In Oncology With Candel Therapeutics' Paul Peter Tak, M.D., Ph.D.
Source: Life Science Leader
On this week's episode of the Business of Biotech, Paul Peter Tak, M.D., Ph.D., CEO at Candel Therapeutics, talks about the path from Phase 3 data to BLA submission for aglatimagene in localized prostate cancer and why “in situ immunization” could change how solid tumors are treated.
Access The Video!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.
Subscribe to Life Science Leader
X
Subscribe to Life Science Leader